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Background: Osteoporosis has a multifactorial pathogenesis characterized by a combination of low bone mass and
increased fragility. In our study, we focused on the effects of polymorphisms in CER1 and DKK1 genes, recently
reported as important susceptibility genes for osteoporosis, on bone mineral density (BMD) and bone markers in
osteoporotic women. Our objective was to evaluate the effect of CER1 and DKK1 variations in 607 postmenopausal
women. The entire DKK1 gene sequence and five selected CER1 SNPs were amplified and resequenced to assess
whether there is a correlation between these genes and BMD, early menopause, and bone turnover markers in
osteoporotic patients.
Results: Osteoporotic women seem to suffer menopause 2 years earlier than the control group. The entire DKK1
gene sequence analysis revealed six variations. There was no correlation between the six DKK1 variations and
osteoporosis, in contrast to the five common CER1 variations that were significantly associated with BMD.
Additionally, osteoporotic patients with rs3747532 and rs7022304 CER1 variations had significantly higher serum
levels of parathyroid hormone and calcitonin and lower serum levels of osteocalcin and IGF-1.
Conclusions: No significant association between the studied DKK1 variations and osteoporosis was found, while
CER1 variations seem to play a significant role in the determination of osteoporosis and a potential predictive role,
combined with bone markers, in postmenopausal osteoporotic women.
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Osteoporosis is a complex multifactorial disease charac-
terized by low bone mass with a consequent increase in
bone fragility, especially in the hips, spine, and wrist [1].
According to evidence arising from large observational
studies [2,3] that is already part of the World Health
Organization (WHO) and European guidelines for the
management of osteoporosis, the clinical significance of
osteoporosis is its established association with fracture
risk, which is also mediated by a number of other epi-
demiological and clinical factors [4]. Apart from these
traditional risk factors and due to a knowledge gap* Correspondence: pankollia@biol.uoa.gr
1Laboratory of Human Genetics, Department of Genetics & Biotechnology,
Faculty of Biology, National and Kapodistrian University of Athens, Athens
15701, Greece
Full list of author information is available at the end of the article
© 2013 Koromila et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orregarding fracture susceptibility, various bone-related
biomarkers have also been proposed as potential frac-
ture risk factors [5,6]. Several bone markers are mea-
sured in the serum in order to evaluate the bone
turnover and to predict the fracture risk in elderly
women [7,8].
The recently evolved novel concept of fat-bone inter-
actions suggests that adipose tissue might profoundly
affect bone formation and/or resorption [9]. Adipokines
such as leptin have recently emerged as mediators of the
protective effects of fat on bone tissue [10,11]. Moreover,
serum osteocalcin (OC) has been considered as a spe-
cific marker of osteoblast function since OC levels cor-
relate with bone formation rates. Insulin-like growth
factor-1 (IGF-1) is also essential for the development
and growth of the skeleton and maintenance of boneal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of the osteoporotic (N = 457) and
control (N = 150) groups
Control Osteoporotic
Age (years), mean [SD] 68.3 [11.2] 70.1 [11.3]




Years since menopause, mean [SD] 18.1 [11.7] 21.0 [12]
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formation by regulating the functions of differentiated os-
teoblasts [12]. Furthermore, parathyroid hormone (PTH)
is an important regulator of bone turnover because of the
indirect stimulation of bone resorption through osteo-
clasts. While PTH increases the concentration of calcium
in the blood, calcitonin (CT) reduces blood calcium and
inhibits osteoclast activity in the bone.
In recent years, numerous gene polymorphisms (single
nucleotide polymorphisms (SNPs)) have been associated
with bone mineral density (BMD) and/or risk of fracture,
identified either by a candidate gene approach or by
genome-wide association studies (GWAS) [13,14]. The
transforming growth factor beta (TGFbeta) and Wnt sig-
naling pathways have a functional role in bone mass
regulation, influencing both osteoblasts and osteoclasts.
The dickkopf Wnt signaling pathway inhibitor 1 (DKK1)
gene in humans is located in 10q11.2 (NM_012242.2). The
DKK1 gene belongs to a small gene family of four mem-
bers (DKK1–4) that encodes secreted proteins that typi-
cally inhibit canonical Wnt signaling by binding to the re-
ceptors of two different families, namely LRP5-LRP6 [15]
and Kremen 1-Kremen 2 [16]. The extracellular regions of
LRP5-LRP6 interact with the Wnt antagonists DKK1 and
sclerostin (SOST). In molecular network analyses, SOST
shows a strong, positive correlation with DKK1 [17,18].
Mice overexpressing Dkk1 develop severe osteopenia, in
part due to diminished bone formation [19]. Finally,
overexpression of DKK1 in glucocorticoid-induced osteo-
porosis [18,20,21] as well as in osteosarcoma and osteo-
lytic metastatic bone disease in multiple myeloma [22-24]
led to the hypothesis that DKK1 is a strong candidate gene
for the regulation of bone homeostasis.
Additionally, bone morphogenetic proteins (BMPs)
are multifunctional growth factors that belong to the
TGFbeta superfamily and have a significant role in bone
remodeling. The activity of BMPs is controlled at diffe-
rent molecular levels [25]. A series of BMP antagonists
bind BMP ligands and inhibit BMP functions. The
human cerberus 1, DAN family BMP antagonist gene
(CER1; NM_005454.2), a candidate gene for osteopo-
rosis located in 9p23-p22, belongs to a distinct group of
BMP antagonists (ligand traps) that can bind directly to
BMPs and inhibit their activity [26-33].
In this case–control study, the whole DKK1 gene se-
quence was replicated for the first time, as a possible
regulator of bone mass as previously reported on GWAS
[14]. Furthermore, the five common genetic variations of
the CER1 gene previously reported by Koromila et al.
[32] were verified in a larger cohort. The correlation
among the aforementioned SNPs with BMD, osteocalcin,
and some bone turnover regulators as well as with
menopause age of Greek postmenopausal women re-
vealed significant conclusions.Results
General characteristics of the assessed cohort
We analyzed 457 osteoporotic and 150 healthy postmeno-
pausal women. As expected, the two groups revealed a
statistically significantly difference (p < 0.001) in the mean
T-score and the fracture record. The two groups were
found to be similar in their other general characteristics,
with the exception of mean years since menopause (p <
0.05). The majority of the osteoporotic group (78.9%) suf-
fered from at least one fracture (vertebral, hip, or other
fractures). Further details of both the osteoporotic and
control groups are presented in Table 1.
DKK1 and CER1 gene variants
The analysis of the whole DKK1 gene sequence revealed six
SNPs. Among the DKK1 SNPs, rs11001560, rs11815201,
rs112910014, and rs1569198 are intron-located; rs74711339
is located in the 3′ untranslated region (UTR); and the syn-
onymous variation rs2241529 is located in exon 2. No sig-
nificant association for the identified DKK1 variants and
BMD was found. Moreover, we found no significant associ-
ation between DKK1 and age, body mass index (BMI),
smoking, early menopause, or bone markers.
Genotype distributions of all CER1 alleles were in
Hardy-Weinberg equilibrium (p < 0.05). Although, among
the five CER1 SNPs, rs3747532 and rs1494360 are not in-
dependent ones (r2 > 0.8) while the other three SNPs are
not on any array according to SNAP analysis, we observed
a statistically significant association for all five CER1 SNPs
(Table 2). Specifically, the rs1494360 SNP was independ-
ently associated with hip fractures (p = 0.043) or the
Table 2 Association of CER1 genotypes with T-score and multiple logistic regression analysis for fracture prediction
CER1 genotypes Total cohort Osteoporotic patients
T-score Vertebral fracture Hip fracture Any fracture
Mean SD P OR (95% CI) P OR (95% CI) P OR (95% CI) P
rs3747532: (C/C) −1.1 1.6 <0.05 1.71 (0.2–3.13) NS 1.63 (0.76–3.48) NS 1.79 (0.79–4.09) NS
(C/G), (G/G) −2.0 1.0
rs1494360: (G/G) −1.1 1.4 <0.05 2.12 (0.23–13.54) NS 1.98 (0.3–23.22) <0.05 1.38 (0.49–15.5) <0.01
G/T), (T/T) −2.4 1.1
rs7022304: (A/A) −1.1 1.5 <0.05 0.90 (0.23–3.49) NS 1.22 (0.49–3.01) NS 1.47 (0.49–8.1) NS
(A/G), (G/G) −2.2 1.2
rs17289263: (A/A) −1.0 1.4 <0.05 1.55 (0.42–5.04) NS 1.15 (0.48–2.75) NS 2.18 (0.61–5.2) NS
(A/G), (G/G) −2.2 1.2
rs74434454: (T/T) −1.0 1.5 <0.05 1.13 (0.46–3.72) NS 1.90 (0.34–10.56) NS 1.98 (0.3–13.22) NS
(T/C), (C/C) −2.2 1.1
Significant values are shown in italics; NS not significant.
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regression analysis was performed for the prediction of
fractures in the osteoporotic patients from the CER1 se-
quence variations, adjusted for age, sex, smoking, BMI,
years since menopause, and calcium intake, confirming
our previous report [32]. Homozygotes or heterozygotes
for the above SNP were at a higher risk of hip fracture
(1.98-fold) and any fracture (1.38-fold). On the other hand,
no significant association between DKK1 and BMD, age,
BMI, smoking, years since menopause, calcium intake, or
fracture was found.
Bone markers
Among the studied bone markers previously referred, the
serum levels of leptin did not change between osteopo-
rotic patients and controls at any CER1 variation. Com-
pared to controls' values as well as to normal values' range
per bone marker, a statistically significant number of
osteoporotic patients with minor alleles of rs3747532 and
rs7022304 had higher serum levels of PTH (mean = 78.4,
standard deviation (SD) = 41.23) and CT (mean = 10.1,
SD = 4.13) and lower serum levels of OC (mean = 4.9,
SD = 3.52) and IGF-1 (mean = 80.2, SD = 62.62) (Figure 1).
In addition, only serum OC levels and patients with hip
fractures were significantly correlated and were found to
be lower than total osteoporotic and control groups (p =
0.012), supporting the previous reports of Akesson et al.
[34,35]. No significant association was found between the
aforementioned bone markers and the age of menopause.
Menopause
Postmenopausal women with osteoporosis seem to suf-
fer menopause 2 years earlier than healthy women (p ≤
0.05) as it is presented in Table 3. In addition, patients
with hip fractures suffered menopause significantly earl-
ier compared to the control group. However, our resultsdid not verify an association between sequence varia-
tions of DKK1 and CER1 genes and bone marker serum
levels or menopause age in the osteoporotic or in the
total cohort group (osteoporotic and control).Discussion
Most genetic studies on osteoporosis, until now, have fo-
cused on the regulation of BMD. A number of them
suggest an important genetic component in the deter-
mination of peak bone mass and, in some instances, in
the susceptibility to subsequent fractures.
In our study, we investigated the possible association
of two important susceptibility genes for osteoporosis,
DKK1 and CER1, that participate in Wnt and TGFbeta
signaling pathways, respectively, and are known for their
functional role in bone mass regulation. The DKK1 gene
is able to modulate canonical Wnt signaling, and be-
cause of the established role of this pathway in the
regulation of bone strength, this study aimed at under-
standing the influence of common genetic variations in
DKK1 and CER1 genes on BMD, bone markers, and age
of menopause. In a large genome-wide linkage scan,
Ralston et al. [36] already suggested that the chromo-
somal region 10q21 containing the DKK1 gene was spe-
cifically associated with the regulation of BMD in men.
Our findings for two DKK1 variations, rs2241529 and
rs1569198, support the previous report of Piters et al.
[18] in the male population, while our report is the first
in Caucasian women. In addition, the recent meta-
analysis of GWAS of Estrada et al. revealed no cor-
relation with any variation inside the DKK1 gene
sequence, although a variation upstream of the DKK1
gene was significantly associated with FN-BMD (p =
1.3 × 10−5) and LS-BMD (p = 3.2 × 10−4) as well as with
fractures [14].
Figure 1 CER1 genotypes in postmenopausal women (A) and correlation with abnormal bone marker levels in osteoporotic
patients (B).
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well as the report of Tang et al. in southern Chinese
women [33] suggest a significant association between
CER1 variations and BMD and/or fragility risk. Among all
CER1 sequence variations studied, only the rs3747532
SNP, located in exon 1, results in an Ala>Gly amino acid
change, but both amino acids are classified as nonpolar.
Both rs1494360 and rs7022304 SNPs are located in in-
trons, rs74434454 is located in the 3′UTR, and the syn-
onymous rs17289263 SNP is located in exon 2. Moreover,Table 3 Menopause age and serum OC value correlation with
groups
Study group Age of menopaus
Mean SD
Control 51.2 0.95
Osteoporotic total 49.1 12.33
Osteoporotic hip fracture 48.6 5.85
Osteoporotic vertebral fracture 50.0 4.13mice studies suggested that the CER1 gene is an inhibitor
of BMPs. BMP signaling is very important in bone devel-
opment; it is not surprising that variations in BMP antago-
nists may affect skeletogenesis and BMD variations in
humans (e.g., the sclerosteosis/van Buchem disease gene,
which is caused by mutations in SOST) [37].
This is the first report on the correlation of rs3747532,
rs1494360, rs7022304, rs17289263, and rs74434454 CER1
variations with early menopause and bone markers.
When CER1 variations were correlated with the age ofcontrol and osteoporotic (total, hip/vertebral fracture)
e OC (5–25 ng/ml)
P Mean SD P
0.041 6.2 3.38 0.752
5.4 4.75
0.024 4.7 4.57 0.012
0.072 5.3 2.97 0.197
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osteoporotic women with hip fracture were found to suffer
menopause approximately 2.5 years earlier than the
control group. Osteoporotic patients with rs3747532 or
rs7022304 CER1 variations were found to have signifi-
cantly higher serum levels of PTH and CT, compared to
both controls' and normal values per bone marker. Higher
PTH levels in osteoporotic patients are in accordance with
the indirect stimulation of bone resorption by PTH
through osteoclasts. A further pharmacogenomic analysis
of the above variations with different osteoporotic treat-
ments could be of great interest in order to understand
their mechanism. Both rs3747532 and rs7022304 varia-
tions were associated with low levels of OC and IGF-1 in
osteoporotic postmenopausal women. Furthermore, low
serum values of OC were associated with osteoporotic hip
fractures, concluding that bone formation, as assessed by
OC, is apparently lower in elderly women who sustain a
hip fracture. Follow-up measurements in osteoporotic pa-
tients' serum samples, after 6 months and 1 year of frac-
ture or starting therapy, will possibly show a stronger
correlation with the CER1 gene, leading to a new insight
into personalized therapy of osteoporosis.
Conclusions
Our study underlines a significant association of two
sequence variations of the CER1 gene with PTH, CT,
OC, and IGF-1 in a Hellenic cohort of postmenopausal
women. The studied DKK1 SNPs seem to have no correl-
ation with either the bone markers or the age of meno-
pause, while the association of the CER1 gene with bone
markers supports its previously reported correlation with
osteoporosis and suggests its potential role as a predictive
marker of osteoporosis and hip fracture in postmeno-
pausal women. In further GWAS, both the studied CER1
and DKK1 variations should be included in order to evalu-
ate their biological role in osteoporosis.
Methods
Subjects
In this case–control study, peripheral blood samples
were collected from 700 postmenopausal Greek women,
who were treated at the Department of Orthopaedic
Surgery of the University Hospital of Thessalia in La-
rissa, Greece, and gave their informed consent prior to
their inclusion in the study. All the subjects of the
present study underwent a physical examination and
were interviewed using a structured questionnaire to ob-
tain information on age, BMD, age of menopause, frac-
ture, family history of osteoporosis and fracture, medical
and reproductive history, smoking, alcohol intake, phys-
ical activity, and other secondary causes. Subjects were
excluded from this study if they had diseases known to
affect bone metabolism, were premature to menopause(absence of menstruation for at least 12 months, age <45
years), or had a history of drug use that could affect
bone turnover and BMD. Moreover, high-trauma frac-
tures including major trauma occurring during a motor
vehicle accident or a fall from more than the standing
height were excluded. Therefore, only 655 postmeno-
pausal women met the inclusion criteria, of which 457
individuals were osteoporotic and 150 were normal,
according to their dual-energy X-ray absorptiometry
(DXA) findings (Table 1). In order to avoid misclassifica-
tion and a potential effect dilution, 48 subjects with
‘gray-zone’ T-scores ranging between −1 and −2.5 were
excluded from the study; thus, the study included 607
subjects. The study was approved by the Ethics Commit-
tee of the University of Thessalia, Larissa, Greece, and
conducted according to the Declaration of Helsinki.
T-score
BMD was measured at the femoral neck and at the lumbar
spine (L2 to L4) by DXA. Cases were defined as subjects
with a low BMD (T-score ≤−2.5) at either the spine or the
hip, which was equivalent to osteoporosis according to the
WHO definition [38]; control subjects were individuals
with normal BMD (T-score >−1) without a history of
fracture.
Bone markers
Patients and controls were fasted for at least 12 h. Venous
blood samples were drawn in the morning between 8:00
and 9:00 a.m., and patients' samples were measured within
a mean of 12 h (±5 h) of fracture and before starting treat-
ment. The samples were immediately centrifuged and
stored at −80°C for further analysis. Total serum leptin and
IGF-1 levels were measured using human radioimmuno-
assay (RIA) diagnostic kits (KIPMR44 and KIP1588, re-
spectively, DIASource Europe SA, Louvain-La-Neuve,
Belgium). The leptin kit is suited for human leptin, and no
cross-reactivity has been found with other proteins such as
insulin or IGF-1. The sensitivity of the leptin assay is 0.1
ng/ml, with a calibrators' range of 0–64 ng/ml. The IGF-1
kit has a sensitivity of 3.4 ng/ml and a calibrators' range of
0–1,529 ng/ml, with no cross-reactivity to insulin and
growth hormone. Serum human intact osteocalcin, para-
thyroid hormone, and calcitonin values were measured
using human immunoradiometric assay (IRMA) diagnos-
tic kits (KIP1381, KIP1491, and KIP0429, respectively,
DIASource Europe SA, Louvain-La-Neuve, Belgium). The
OC kit has a sensitivity of 0.22 ng/ml and a calibrators'
range of 0–69 ng/ml, with no cross-reactivity to N-
terminal and C-terminal fragments. The PTH kit has a
sensitivity of 4.1 pg/ml and a calibrators' range of 0–973
pg/ml and does not cross-react with PTH fragments and
PTH-related proteins. The CT kit has a sensitivity of 0.9
pg/ml and a calibrators' range of 0–674 pg/ml. No
Table 4 Primers for PCR and sequencing of the DKK1 gene
Localization
(nucleotide)
Forward primer Reverse primer
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up to 100 ng/ml) with calcitonin gene-related peptide
(CGRP), salmon calcitonin, katacalcin (PDN-21), and pro-
calcitonin N-terminal. Moreover, all RIA and IRMA kits
are calibrated against valid international standards. The ra-
diotracer used in all kits is iodine-125 (125I, half-life t1/2 60
days, 35.5-keV gamma radiation, 27–32-keV X-rays, no
beta radiation). All sample assays were performed in
duplicate and were included in the same run for each
biological parameter. If the difference between duplicate
results of a sample was more than 5%, the sample assay
was repeated, and the in-run coefficients of variation were
3.9% for leptin, 3.4% for IGF-1, 2.9% for OC, 3.1% for
PTH, and 2.8% for CT. An automatic gamma counter
(Cobra II/5010, Packard, Conroe, TX, USA) was used to
count the radioactivity and calculate the results.
Amplification and resequencing of the human CER1 and
DKK1 genes
Genomic DNA was isolated using QIAamp DNA Blood
Mini Kit (QIAGEN, Venlo, Netherlands). CER1 and
DKK1 genes were polymerase chain reaction (PCR)-
amplified and resequenced to identify the underlying se-
quence variation. Eleven pairs of primers, four pairs for
CER1 and seven pairs for DKK1 (Table 4), were designed
in order to cover the five variants of the CER1 gene pre-
viously reported by Koromila et al. [32] as well as the
entire sequence of the DKK1 gene (3,377 bp) (Figure 2).
Sequencing was performed twice per sample (two inde-
pendent PCR products) in both forward and reverse ori-
entations. Genomic DNA information was obtained
from GenBank wild-type sequences [CER1: chromosome
9, NC_000009.11 (14719731..14722715), MIM: 603777,Figure 2 Studied variations in the genomic structure of the DKK1 genID: 9350; DKK1: chromosome 10, NC_000010.10
(54074041..54077417), MIM: 605189, ID: 22943]. Sequence
variants were verified using the MegaBACE 1000 DNA Se-
quencing System (Amersham Biosciences, Piscataway, NJ,
USA). Six variants, rs2241529, rs11001560, rs11815201,
rs112910014, rs1569198, and rs74711339, in the DKK1
gene were detected (Figure 2), and five common variants
were analyzed in CER1 by multiple sequence alignments
using Chromas Lite 2.01 software and BLAST analysis in
the cohort. Five common SNPs in the CER1 gene, namely
rs3747532 (c.194C>G, exon 1), rs1494360 (c.507+506G>T,
intron), rs7022304 (c.508-182A>G, intron), rs17289263
(c.531A>G, exon 2), and rs74434454 (c.*121T>C, 3′UTR),
were resequenced. Among these five CER1 SNPs, only
rs3747532, which is located in exon 1, causes an amino acid
change from Ala to Gly. Six SNPs in DKK1 (Figure 2) were
analyzed as well through direct resequencing. Among the
DKK1 SNPs, only rs2241529 is exon-located (c.318A>G,
exon 2) and causes an amino acid substitution, while
rs11001560, rs11815201, rs112910014, and rs1569198 are
located in introns and rs74711339 in 3′UTR. An associ-
ation between DKK1 variations and BMD could not be
attempted in our dataset (osteoporotic and control).
Statistical analysis
Continuous variables are presented as mean and SD,
while categorical variables are presented as absolute and
relative frequencies. The Hardy-Weinberg equilibrium
(HWE) was assessed in the control samples by applying
an exact test. Deviation from HWE was considered
nominally statistically significant at the p < 0.05 level
[39,40]. Genotype frequency differences between cases
and controls were tested using unconditional logistice.
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and 95% confidence intervals (CIs) were estimated under
the log-additive model, using the major allele in the
Greek control population as reference. Odds ratios thus
represent the risk conferred per copy of the minor allele.
Secondary analyses also examined recessive and domin-
ant models of inheritance. Pearson's correlation coeffi-
cient (r) was used to estimate the correlations in minor
allele frequencies between our study and the HapMap
CEU population [26]. The overall correlation between
ORs in the Greek population and the GWAS population
where each SNP was first discovered was also calculated.
The power of the study to detect ORs similar to those
previously found in the GWAS, given the allele frequen-
cies observed in the Greek population, was estimated at
an α value of 0.05.
Statistical analyses were run in Stata, version 10.1 (Col-
lege Station, TX, USA). P values for association are two-
tailed and not adjusted for multiple comparisons since this
is a replication effort for associations that already have
robust statistical support. Student's t tests were used for
the comparison of mean values between osteoporotic and
control groups. Analyses were conducted using SPSS stati-
stical software (version 17.0). Design and reporting follow
the STREGA guidance [41].
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